Benefits were consistent across glomerular disease subtypes, too

Kidney Compass: Navigating Clinical Trials | Podcasts | HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and inter...

Podcast Episode · Kidney Compass: Navigating Clinical Trials · 2025-11-13 · 17m

in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

In this prespecified interim analysis, treatment with atacicept resulted in a significantly greater reduction in proteinuria than placebo at week 36 in patients with IgA nephropathy. (Funded by Vera Therapeutics; ORIGIN 3 ClinicalTrials.gov number, NCT04716231.).

This meta-analysis examines whether estimated glomerular filtration rate or degree of albuminuria, as measured by urinary albumin to creatinine ratio, modifies the effects of sodium-glucose cotranspor...

Discover the unique high science & discussion program for CVCT 2025 (Global CardioVascular Trialists Forum), December 8-10, at the Mayflower Hotel, Washington DC

The American Society of Nephrology announced details of the plenary sessions scheduled to take place at Kidney Week 2025, which will take place November 6-9, in Houston, Texas.

Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani

Podcast Episode · Kidney Compass: Navigating Clinical Trials · 2025-06-06 · 22m

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.

Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. W...

With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.

Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...